A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
about
Therapeutic radionuclides in nuclear medicine: current and future prospectsImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteIrigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in Lung cancer cells.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylationBeyond natural antibodies: the power of in vitro display technologies.A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.DAMPening inflammation by modulating TLR signalling.From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Fibronectins in vascular morphogenesisA chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancerThe TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccineGlycosylation profiles determine extravasation and disease-targeting properties of armed antibodiesA highly functional synthetic phage display library containing over 40 billion human antibody clones.Recombinant renewable polyclonal antibodies.Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule.Force-induced fibronectin assembly and matrix remodeling in a 3D microtissue model of tissue morphogenesis.Circulating fibronectin controls tumor growthThe antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer.Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.Latent cytokines for targeted therapy of inflammatory disorders.Overcoming multidrug resistance with nanomedicines.Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
P2860
Q26861998-5843114E-5CA8-4EA0-9A1A-15F1DB38F14AQ28066935-716053A6-0574-4719-A392-6096E182A30AQ30828838-71412825-8A9A-4FA1-95E0-3D8928B337B6Q33605532-04628E51-13AA-4154-B032-3E4378BFAFCCQ33651167-6F4ADA74-7BC0-454A-936B-33119B53FB23Q33742283-43FEEA5D-02FD-46FC-BD63-7E15EC4679E1Q33841864-EE1C7D8C-E6B5-4419-8DF2-1042854EF239Q33870905-A26D39E1-E243-4AE6-8770-5335BB62B385Q34035570-CB8A53C0-4F1F-4F72-82CC-74C00326D6EEQ34048030-F464360D-1FBC-4D76-88F9-F742B36C7443Q34083054-AD4A18E8-896C-4784-90A4-B05AB4AC4AE0Q34230590-7A002421-C3EB-4087-9B94-324E47C78FE1Q34385892-F76E9B40-BF36-4A25-BCA4-D141CC2C9529Q34604585-9C87F354-49A0-437E-AFA3-15CE9687CD93Q34746019-E2F0FAE6-1D5D-424D-A304-F8EAE78FCC9FQ35027232-FAAD3EE4-ACDF-4A9F-AF58-A1EE31DEF6C8Q35113904-8E044FD0-F9B8-4686-B7E1-313FD37449E8Q35129041-034F72A8-8AE8-4DD9-AFFB-A5D6440DE00DQ35192223-F9FC7A6F-6D57-43F0-AACE-903B97A3073AQ35531929-4933BC1F-97D6-4D2D-96E4-C1C0D3674DA5Q35755602-D51EF8CD-1949-48FE-BE59-04330BB6CB42Q36651568-F444267D-3380-417B-8E0E-78A71BF442F8Q37061025-D1B6F488-4D15-46BF-B583-6550E7190DA9Q37185752-430E097A-6CEC-470E-BD3A-870FD51D7091Q37222913-15BDAB3C-8B12-47A9-9447-6A93EE1C9AF4Q37330712-4630F007-3EED-44D8-979F-0F6C6064C8BBQ37354308-3220A9F7-EDE1-41CB-9AF2-4DB6FB0A0E33Q37453905-5E7BDBB2-7B25-479A-8498-EB9907176F37Q37485709-F4BBFE93-0FF6-452A-86C4-98E465060C89Q37559740-68A61FDA-C929-41CC-A9D5-FC515E9341B5Q37593714-D030B1F3-DDBF-4909-8E57-DD9235E24A6BQ37690616-795AD7C5-8180-44DD-839C-EBC4248BCC64Q38167818-864824BF-C7A4-494F-8C20-D410A5B24EA9Q38249954-E577B67D-D5B1-4864-A6A1-9082ED26D631Q38842103-E6397702-4A55-4812-BE37-C240CC3E6EAFQ38873741-A3761B3D-AFB2-4565-B2F0-97F845EF72B2Q38905573-AB6A9E67-09F4-4664-AE09-86F8FB2F2E89Q38988662-5797BCA2-C7A4-4A5F-AEA4-667227987322Q38998638-240CDA70-EF1A-46E3-B1A8-B0094A3C7530Q39100229-426BE38F-B72C-4CC1-B2F0-395F0FCB6000
P2860
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A high-affinity human monoclon ...... tumor neo-vasculature in vivo.
@en
type
label
A high-affinity human monoclon ...... tumor neo-vasculature in vivo.
@en
prefLabel
A high-affinity human monoclon ...... tumor neo-vasculature in vivo.
@en
P2093
P2860
P356
P1476
A high-affinity human monoclon ...... tumor neo-vasculature in vivo.
@en
P2093
Alessandra Villa
Christoph Rösli
Christoph Schliemann
Eveline Trachsel
Jascha-N Rybak
Laura Borsi
Manuela Kaspar
Roberto Sommavilla
P2860
P304
P356
10.1002/IJC.23408
P50
P577
2008-06-01T00:00:00Z